Breast Breaking News

Development and Validation of the RSClinN1 Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer

Adjuvant chemotherapy in T1abN0 breast cancer with a high 21‑gene recurrence score ( 25) a 10‑year follow‑up in a real‑world cohort

De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial

In‑Breast Tumor Progression During Neoadjuvant Chemotherapy: Impact on and Factors Influencing Distant Recurrence‑Free Survival

A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2- Negative Early Breast Cancer: Results from the EMBER-2 Study

Real‑World Implications of the SOUND Trial

Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I SPY2 clinical trial

Margin Width and Local Recurrence in Patients with Phyllodes Tumors of the Breast